Research progress in animal models of dry eye disease: Types, mechanisms, and application prospects

Abstract

Dry eye disease (DED) is a prevalent and complex multifactorial ocular surface disorder, leading to significant visual discomfort and diminished quality of life. Animal models are indispensable tools for investigating DED pathology and evaluating therapeutic interventions. This review aims to systematically summarize the primary types of animal models of DED, detail their establishment methods and pathophysiological features, explore their value in elucidating key mechanisms, critically assess their strengths and limitations, and discuss their application prospects. A comprehensive literature search was conducted in electronic databases, including PubMed, Web of Science, and Google Scholar, with a primary focus on literature published within the past decade. Diverse animal models successfully replicate core features of different DED subtypes. Aqueous-deficient models (e.g., surgical excision, scopolamine) mimic tear volume reduction and lacrimal gland inflammation. Evaporative models (e.g., desiccating stress, benzalkonium chloride) effectively simulate tear film lipid layer dysfunction and increased evaporation. Neurogenic models reveal the critical role of neural regulation and neuroinflammation, whereas multifactorial models (e.g., autoimmune, environment-drug combinations) offer high clinical relevance by integrating multiple pathogenic factors. These models have been instrumental in identifying key inflammatory signaling pathways (e.g., NF-κB), immune cell infiltration dynamics, and corneal nerve morphological and functional changes. Animal models are crucial for advancing our understanding of DED pathogenesis and developing novel therapies. The rational selection and application of appropriate models, based on research objectives, are paramount for enhancing translational relevance. These efforts are essential for bridging the translational gap between preclinical research and clinical application.

Keywords

3R principles / animal models / aqueous deficiency / dry eye disease / evaporative dry eye / inflammation / neuropathy / preclinical research

References

[1] Sheppard J, Shen Lee B, Periman LM. Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists. Ann Med. 2023; 55(1): 241-252.

[2] Villani E, Barabino S, Giannaccare G, Di Zazzo A, Aragona P, Rolando M. From symptoms to satisfaction: optimizing patient-centered care in dry eye Disease. J Clin Med. 2025; 14(1):196.

[3] McCann P, Abraham AG, Mukhopadhyay A, et al. Prevalence and incidence of dry eye and meibomian gland dysfunction in the United States: a systematic review and meta-analysis. JAMA Ophthalmol. 2022; 140(12): 1181-1192.

[4] Messmer EM. Pathophysiology of dry eye disease and novel therapeutic targets. Exp Eye Res. 2022; 217:108944.

[5] Macri A, Tarallo M, Iester M. Imaging approaches for the diagnosis of dry eye: a review. Diagnostics. 2026; 16(1):126.

[6] Lin Y, Zhang Y, Shi K, Wu H, Ou S. Advances in clinical examination of lacrimal gland. Front Med (Lausanne). 2023; 10:1257209.

[7] Kwon J, Moghtader A, Kang C, et al. Overview of dry eye disease for primary care physicians. Medicina (Kaunas). 2025; 61(3):460.

[8] Rolando M, Merayo-Lloves J. Management strategies for evaporative dry eye disease and future perspective. Curr Eye Res. 2022; 47(6): 813-823.

[9] Rao SK, Gokhale N, Matalia H, Mehta P. Inflammation and dry eye disease—where are we? Int J Ophthalmol. 2022; 15(5): 820-827.

[10] Fang X, Lan G, Lin Y, et al. Inflammation due to ocular surface homeostasis imbalance caused by pterygia: tear lymphotoxin-alpha study and a literature review. J Ophthalmic Inflamm Infect. 2024; 14(1): 28.

[11] Rahman MM, Kim DH, Park CK, Kim YH. Experimental models, induction protocols, and measured parameters in dry eye disease: focusing on practical implications for experimental research. Int J Mol Sci. 2021; 22(22):12102.

[12] Zhu J, Inomata T, Shih KC, et al. Application of animal models in interpreting dry eye disease. Front Med (Lausanne). 2022; 9:830592.

[13] Chang Y-A, Wu Y-Y, Lin C-T, et al. Animal models of dry eye: their strengths and limitations for studying human dry eye disease. J Chin Med Assoc. 2021; 84(5): 459-464.

[14] Huang W, Tourmouzis K, Perry H, et al. Animal models of dry eye disease: useful, varied and evolving (review). Exp Ther Med. 2021; 22(6): 1394.

[15] Wang J, Zhang Z, Liu Y, et al. Identification of ferroptosis-related genes in dry eye disease and their effects on inflammatory response and immune infiltration. Gene. 2026; 974:149853.

[16] Lin C, Wu J, Jing Y, et al. NF-κB/IL-6 axis drives impaired corneal wound healing in aqueous-deficient dry eye. Front Immunol. 2025; 16:1684290.

[17] Xu K, Liu XN, Zhang HB, et al. Tear film instability is associated with weakened colocalization between occludin and MUC5AC in scopolamine-induced dry eye disease (DED) rats. Int Ophthalmol. 2023; 43(2): 463-473.

[18] Zhang D, Chen T, Liang Q, et al. A first-in-human, prospective pilot trial of umbilical cord-derived mesenchymal stem cell eye drops therapy for patients with refractory non-Sjögren's and Sjögren's syndrome dry eye disease. Stem Cell Res Ther. 2025; 16(1):202.

[19] Kravchenko SV, Myasnikova VV, Sakhnov SN. The chick embryo and its structures as a model system for experimental ophthalmology. Bull Exp Biol Med. 2023; 174(4): 405-412.

[20] Joshi V, Mohapatra S, Ahmad Dar MA, et al. Tear film-based diagnostics and emerging tissue engineering approaches in personalized dry eye disease management. Semin Ophthalmol. 2026; 41(2): 342-355.

[21] Li Q, Wong HL, Ip YL, et al. Current microfluidic platforms for reverse engineering of cornea. Mater Today Bio. 2023; 20:100634.

[22] Musayeva A, Jiang S, Ruan Y, et al. Aged mice devoid of the M(3) muscarinic acetylcholine receptor develop mild dry eye disease. Int J Mol Sci. 2021; 22(11):6133.

[23] Zhang M, Tian X, Wu Y, et al. Establishment of a mouse model of aqueous deficiency dry eye. J Vis Exp. 2024;(213).

[24] Li S, Xiao Y, Tang Y, et al. A rat dry eye model with lacrimal gland dysfunction induced by scopolamine. J Vis Exp. 2024;(204).

[25] Sullivan C, Lee J, Bushey W, et al. Evidence for a phenotypic switch in corneal afferents after lacrimal gland excision. Exp Eye Res. 2022; 218:109005.

[26] Qu M, Wang Q, Bai X, et al. A gatekeeper sympathetic control of lacrimal tear secretion and dry eye onset through the NA-Adra1a-Ucp2 pathway. Nat Commun. 2025; 16(1): 5215.

[27] Toribio D, Morokuma J, Pellino D, Hardt M, Zoukhri D. Quantitative changes in the proteome of chronically inflamed lacrimal glands from a Sjögren's disease animal model. Invest Ophthalmol Vis Sci. 2025; 66(4):44.

[28] Wang H-H, Chen W-Y, Huang Y-H, et al. Interleukin-20 is involved in dry eye disease and is a potential therapeutic target. J Biomed Sci. 2022; 29(1): 36.

[29] Møller-Hansen M. Mesenchymal stem cell therapy in aqueous deficient dry eye disease. Acta Ophthalmol. 2023; 101(S277): 3-27.

[30] Doctor MB, Basu S. Lacrimal gland insufficiency in aqueous deficiency dry eye disease: recent advances in pathogenesis, diagnosis, and treatment. Semin Ophthalmol. 2022; 37(7–8): 801-812.

[31] Karpecki PM, Nichols KK, Sheppard JD. Addressing excessive evaporation: an unmet need in dry eye disease. Am J Manag Care. 2023; 29(13 Suppl): S239-S247.

[32] Bhujbal S, Rupenthal ID, Steven P, et al. Inflammation in dry eye disease-pathogenesis, preclinical animal models, and treatments. J Ocul Pharmacol Ther. 2024; 40(10): 638-658.

[33] Chaudhari P, Satarker S, Thomas R, et al. Rodent models for dry eye syndrome: standardization using benzalkonium chloride and scopolamine hydrobromide. Life Sci. 2023; 317:121463.

[34] Kessal K, Daull P, Cimbolini N, et al. Comparison of two experimental mouse dry eye models through inflammatory gene set enrichment analysis based on a multiplexed transcriptomic approach. Int J Mol Sci. 2021; 22(19):10770.

[35] Chen J, Qin G, Yu S, et al. Comparison of non-pharmaceutical treatments for evaporative dry eye: a randomised controlled study protocol. BMJ Open. 2024; 14(2):e078727.

[36] Paugh JR, Nguyen T, Sasai A, et al. The efficacy of clinical tests to diagnose evaporative dry eye disease related to meibomian gland dysfunction. J Ophthalmol. 2022; 2022:3889474.

[37] Vidal-Rohr M, Craig JP, Davies LN, Wolffsohn JS. Classification of dry eye disease subtypes. Cont Lens Anterior Eye. 2024; 47(5):102257.

[38] Hisey EA, Galor A, Leonard BC. A comparative review of evaporative dry eye disease and meibomian gland dysfunction in dogs and humans. Vet Ophthalmol. 2023; 26(S1): 16-30.

[39] Narang P, Donthineni PR, D'Souza S, et al. Evaporative dry eye disease due to meibomian gland dysfunction: preferred practice pattern guidelines for diagnosis and treatment. Indian J Ophthalmol. 2023; 71(4): 1348-1356.

[40] Barrientos RT, Godin F, Rocha-de-Lossada C, et al. Ophthalmological approach for the diagnosis of dry eye disease in patients with Sjogren's syndrome. Life (Basel). 2022; 12(11):1899.

[41] Maulvi FA, Desai DT, Kalaiselvan P, et al. Lipid-based eye drop formulations for the management of evaporative dry eyes. Cont Lens Anterior Eye. 2024; 47(3):102154.

[42] Bhatt K, Singh S, Singh K, Kumar S, Dwivedi K. Prevalence of dry eye, its categorization (Dry Eye Workshop II), and pathological correlation: a tertiary care study. Indian J Ophthalmol. 2023; 71(4): 1454-1458.

[43] Bilkhu P, Wolffsohn J, Purslow C. Provocation of the ocular surface to investigate the evaporative pathophysiology of dry eye disease. Cont Lens Anterior Eye. 2021; 44(1): 24-29.

[44] Stolz M. The prevalence of corneal sensitivity loss in patients with and without dry eye disease. Clin Ophthalmol. 2025; 19: 1323-1330.

[45] Kang Y, Hu Q, Li X, et al. Role of tear vasoactive intestinal peptide on dry eyes after laser keratorefractive surgery. BMC Ophthalmol. 2023; 23(1):167.

[46] Yu K, Chen Y, Feng Z, et al. Segmentation and multiparametric evaluation of corneal whorl-like nerves for in vivo confocal microscopy images in dry eye disease. BMJ Open Ophthalmol. 2024; 9(1):e001861.

[47] Chiaretti A, Eftimiadi G, Soligo M, Manni L, Di Giuda D, Calcagni ML. Topical delivery of nerve growth factor for treatment of ocular and brain disorders. Neural Regen Res. 2021; 16(9):1740.

[48] Wareham LK, Holden JM, Bossardet OL, et al. Collagen mimetic peptide repair of the corneal nerve bed in a mouse model of dry eye disease. Front Neurosci. 2023; 17:1148950.

[49] Barros JFF, Sant'ana AMS, Dias LC, et al. Comparison of the effects of corneal and lacrimal gland denervation on the lacrimal functional unit of rats. Arq Bras Oftalmol. 2022; 85(1): 59-67.

[50] McPheeters MT, Blackburn BJ, Dupps WJ, Rollins AM, Jenkins MW. Genetically encoded calcium indicators for in situ functional studies of corneal nerves. Invest Ophthalmol Vis Sci. 2020; 61(13):10.

[51] Soyfoo M, Motulsky E, Sarrand J. Keratoconjunctivitis Sicca in Sjogren disease: diagnostic challenges and therapeutic advances. Int J Mol Sci. 2025; 26(18):8824.

[52] Saram SJ, Thomas MN, Feinberg L, et al. The immunobiology of dry eye disease: a review of the pathogenesis, regulation and therapeutic implications. Int J Mol Sci. 2025; 26(21):10583.

[53] Li L, Jasmer KJ, Camden JM, et al. Early dry eye disease onset in a NOD.H-2h4 mouse model of Sjögren's syndrome. Invest Opthalmol Vis Sci. 2022; 63(6):18.

[54] Baranauskas V, Galgauskas S. Rabbit models of dry eye disease: comparative analysis. Int J Ophthalmol. 2023; 16(8): 1177-1185.

[55] Tu Y, Gu X. THBS1 inhibition alleviates inflammatory response by inhibiting TGF-beta and NLRP3 inflammasome in experimental murine dry eye. Med Mol Morphol. 2025. Epub ahead of print.

[56] Fu T, Lu W, Wu D, Xu L, Wu G. Exploring the immunomodulatory mechanism of total glucosides of paeony on Sjögren's syndrome dry eye disease based on the “gut-eye axis” pathway. Int Ophthalmol. 2025; 45(1):230.

[57] Guo H, Ju Y, Choi M, et al. Supra-lacrimal protein-based carriers for cyclosporine a reduce Th17-mediated autoimmunity in murine model of Sjögren's syndrome. Biomaterials. 2022; 283:121441.

[58] Kuklinski EJ, Yu Y, Ying G-S, et al. Association of ocular surface immune cells with dry eye signs and symptoms in the dry eye assessment and management (DREAM) study. Invest Opthalmol Vis Sci. 2023; 64(12):7.

[59] Zhai Y, Zheng X, Mao Y, et al. Recombinant human Thymosin β4 (rhTβ4) modulates the anti-inflammatory responses to alleviate Benzalkonium chloride (BAC)-induced dry eye disease. Int J Mol Sci. 2022; 23(10):5458.

[60] Wu C-M, Mao J-W, Zhu J-Z, et al. DZ2002 alleviates corneal angiogenesis and inflammation in rodent models of dry eye disease via regulating STAT3-PI3K-Akt-NF-κB pathway. Acta Pharmacol Sin. 2023; 45(1): 166-179.

[61] Han Y, Guo S, Li Y, et al. Berberine ameliorate inflammation and apoptosis via modulating PI3K/AKT/NFκB and MAPK pathway on dry eye. Phytomedicine. 2023; 121:155081.

[62] Gong L, Guan Y, Cho W, et al. A new non-human primate model of desiccating stress-induced dry eye disease. Sci Rep. 2022; 12(1):7957.

[63] Golub VM, Reddy DS. Post-traumatic epilepsy and comorbidities: advanced models, molecular mechanisms, biomarkers, and novel therapeutic interventions. Pharmacol Rev. 2022; 74(2): 387-438.

[64] Hao R, Zhang M, Zhao L, et al. Impact of air pollution on the ocular surface and tear cytokine levels: a multicenter prospective cohort study. Front Med (Lausanne). 2022; 9:909330.

[65] Cartes C, Segovia C, Calonge M, Figueiredo FC. International survey on dry eye diagnosis by experts. Heliyon. 2023; 9(6):e16995.

[66] Jiang X, Xu B, Xu R, et al. A comprehensive analysis of dry eye disease clinical trials (2000-2024): research trends and gaps. Front Pharmacol. 2026; 17:1713433.

[67] Thacker M, Sahoo A, Reddy AA, et al. Benzalkonium chloride-induced dry eye disease animal models: current understanding and potential for translational research. Indian J Ophthalmol. 2023; 71(4): 1256-1262.

[68] Dogru M, Kojima T, Simsek C, Nagata T, Tsubota K. Salivary and lacrimal gland alterations of the epidermal fatty acid-binding protein (E-FABP) in non-obese diabetic mice. Int J Mol Sci. 2022; 23(7):3491.

[69] Qin D-Y, Deng Y-P. Transgenic dry eye mouse models: powerful tools to study dry eye disease. Int J Ophthalmol. 2022; 15(4): 635-645.

[70] Widjaja-Adhi MAK, Chao K, Golczak M. Mouse models in studies on the etiology of evaporative dry eye disease. Exp Eye Res. 2022; 219:109072.

[71] Hisey EA, Wong S, Park S, et al. Meibomian gland lipid alterations and ocular surface sequela in Awat2 knockout murine model of meibomian gland dysfunction and evaporative dry eye disease. Ocul Surf. 2024; 34: 489-503.

[72] Suanno G, Fonteyne P, Ferrari G. Neurosensory abnormalities and stability of a mouse model of dry eye disease. Exp Eye Res. 2023; 232:109516.

[73] Wang J, Gong J, Yang Q, Wang L, Jian Y, Wang P. Interleukin-17 receptor E and C-C motif chemokine receptor 10 identify heterogeneous T helper 17 subsets in a mouse dry eye disease model. Am J Pathol. 2022; 192(2): 332-343.

[74] Alam J, Yazdanpanah G, Ratnapriya R, et al. IL-17 producing lymphocytes cause dry eye and corneal disease with aging in RXRα mutant mouse. Front Med. 2022; 9:849990.

[75] Chen L, Gu C, Yang Y, He T, Zhang Q. Exosomal miR-146a derived from human umbilical cord mesenchymal stem cells alleviates inflammation and apoptosis in dry eye disease by targeting SQSTM1. Exp Eye Res. 2025; 258:110490.

[76] Migeon T, Cordovilla A, Potey A, et al. TRPA1 inhibition reduces ocular pain and corneal neurogenic inflammation in a mouse model of dry eye disease. Biomed Pharmacother. 2025; 192:118625.

[77] Oh JY, Ryu JS, Kim HJ, et al. The link module of human TSG-6 (Link_TSG6) promotes wound healing, suppresses inflammation and improves glandular function in mouse models of dry eye disease. Ocul Surf. 2022; 24: 40-50.

[78] Goo H, Lee YJ, Lee S, Hong N. The anti-inflammatory effect of multi-wavelength light-emitting diode irradiation attenuates dry eye symptoms in a scopolamine-induced mouse model of dry eye. Int J Mol Sci. 2023; 24(24):17493.

[79] Monteiro CSA, Adedara IA, Farombi EO, et al. Nutraceutical potential of olive pomace: insights from cell-based and clinical studies. J Sci Food Agric. 2024; 104(7): 3807-3815.

[80] Lee K, Jeong JW, Shim JJ, Hong HS, Kim JY, Lee JL. Lactobacillus fermentum HY7302 improves dry eye symptoms in a mouse model of Benzalkonium chloride-induced eye dysfunction and human conjunctiva epithelial cells. Int J Mol Sci. 2023; 24(12):10378.

[81] Bao X, Zhong Y, Yang C, et al. T-cell repertoire analysis in the conjunctiva of murine dry eye model. Invest Opthalmol Vis Sci. 2023; 64(3): 14.

[82] Singh S, Sharma S, Basu S. Rabbit models of dry eye disease: current understanding and unmet needs for translational research. Exp Eye Res. 2021; 206:108538.

[83] Fazio N, White E, Tourmouzis K, et al. Monitoring the evolution of dry eye disease in rabbits with advanced ocular keratography: implications for translational studies. Curr Eye Res. 2025; 50(11): 1094-1104.

[84] Butovich IA, Yuksel S, Leonard B, Gadek T, Polans AS, Albert DM. Novel lipids of the rabbit Harderian gland improve tear stability in an animal model of dry eye disease. J Ocul Pharmacol Ther. 2021; 37(10): 545-555.

[85] Honkanen RA, Huang L, Rigas B. A rabbit model of aqueous-deficient dry eye disease induced by Concanavalin A injection into the lacrimal glands: application to drug efficacy studies. J Vis Exp. 2020;(155).

[86] Huang L, Gao H, Wang Z, Zhong Y, Hao L, du Z. Combination nanotherapeutics for dry eye disease treatment in a rabbit model. Int J Nanomedicine. 2021; 16: 3613-3631.

[87] Ozdemir S, Uner B. Prolonged release Niosomes for ocular delivery of loteprednol: ocular distribution assessment on dry eye disease induced rabbit model. AAPS PharmSciTech. 2024; 25(5):119.

[88] Li K, Lin M, Huang K, et al. Therapeutic effect and mechanism of action of pterostilbene nano drugs in dry eye models. Exp Eye Res. 2024; 241:109836.

[89] Baek Y-Y, Sung B, Choi J-S, et al. In vivo efficacy of Imatinib Mesylate, a tyrosine kinase inhibitor, in the treatment of chemically induced dry eye in animal models. Transl Vis Sci Technol. 2021; 10(11):14.

[90] Feng C, Wang W, Gong L, Lin T. Efficacy of topical cyclosporine combined with punctal plugs in treating dry eye disease and inflammation. Curr Eye Res. 2024; 50(2): 148-161.

[91] Ren X, Lin X, Li F, et al. Alleviation of dry eye disease with lyophilized extracellular vesicles. J Control Release. 2025; 385:114044.

[92] Perez-Perdomo M, Gonzalez-Lopez A, Ortega-Llamas L, et al. Identification of a translatable animal model for dry eye disease using comparative analysis of tear proteins across species. Ocul Surf. 2025; 37: 260-272.

[93] Li Z-Z, Zou Y-P, Zhu H, et al. Establishment of a beagle dog model of dry eye disease. Transl Vis Sci Technol. 2023; 12(1):2.

[94] Moreno IY, Cilli EL, Coulson-Thomas VJ. Applied anatomy and morphology of Meibomian glands in the non-human primate. Sci Rep. 2025; 15(1):20749.

[95] Liu P, Jiang P, Tan K, et al. Linarine inhibits inflammatory responses in dry eye disease mice by modulating purinergic receptors. Front Immunol. 2024; 15:1463767.

[96] Wang JN, Fan H, Song JT. Targeting purinergic receptors to attenuate inflammation of dry eye. Purinergic Signal. 2023; 19(1): 199-206.

[97] Kim HY, Lee JD, Kim H, et al. Mass spectrometry (MS)-based metabolomics of plasma and urine in dry eye disease (DED)-induced rat model. J Toxicol Environ Health A. 2024; 88(3): 122-135.

[98] Han R, Gao J, Wang L, et al. MicroRNA-146a negatively regulates inflammation via the IRAK1/TRAF6/NF-κB signaling pathway in dry eye. Sci Rep. 2023; 13(1):11192.

[99] Song D, Yang Q, Li X, Chen K, Tong J, Shen Y. The role of the JAK/STAT3 signaling pathway in acquired corneal diseases. Exp Eye Res. 2024; 238:109748.

[100] Gandolfo S, Ciccia F. JAK/STAT pathway targeting in primary Sjögren syndrome. Rheumatol Immunol Res. 2022; 3(3): 95-102.

[101] Alotaibi S, Papas E, Mobeen R, Ozkan J, Misra SL, Markoulli M. Tear film hTERT and corneal nerve characteristics in dry eye disease. Clin Exp Optom. 2024; 108(4): 450-455.

[102] Hong SC, Ha JH, Lee JK, Jung SH, Kim JC. In vivo anti-inflammation potential of Aster koraiensis extract for dry eye syndrome by the protection of ocular surface. Nutrients. 2020; 12(11):3245.

[103] Gilger BC, Hirsch ML. Therapeutic applications of adeno-associated virus (AAV) gene transfer of HLA-G in the eye. Int J Mol Sci. 2022; 23(7):3465.

[104] Cox KD, Makara M, Maldonado JO, Frantsve-Hawley J, Carsons SE, Sankar V. Exploring the interplay of oral and systemic pathology in Sjogren's disease. J Dent Res. 2026; 105(1): 8-15.

[105] Sun M, Wei Y, Zhang C, Nian H, du B, Wei R. Integrated DNA methylation and transcriptomics analyses of lacrimal glands identify the potential genes implicated in the development of Sjögren's syndrome-related dry eye. J Inflamm Res. 2023; 16: 5697-5714.

[106] Efraim Y, Chen FYT, Stashko C, et al. Alterations in corneal biomechanics underlie early stages of autoimmune-mediated dry eye disease. J Autoimmun. 2020; 114:102500.

[107] Wei Y, Sun M, Zhang X, et al. S100A8/A9 promotes dendritic cell–mediated Th17 cell response in Sjögren's dry eye disease by regulating the Acod1/STAT3 pathway. Invest Ophthalmol Vis Sci. 2025; 66(1): 35.

[108] Ko JH, Kim S, Ryu JS, Song HJ, Oh JY. Interferon-γ elicits the ocular surface pathology mimicking dry eye through direct modulation of resident corneal cells. Cell Death Dis. 2023; 9(1):209.

[109] Alam J, de Paiva CS, Pflugfelder SC. Immune - goblet cell interaction in the conjunctiva. Ocul Surf. 2020; 18(2): 326-334.

[110] Nair AP, D'Souza S, Khamar P, et al. Ocular surface immune cell diversity in dry eye disease. Indian J Ophthalmol. 2023; 71(4): 1237-1247.

[111] Qian Y, Zhang M. The functional roles of IL-33/ST2 axis in ocular diseases. Mediat Inflamm. 2020; 2020:5230716.

[112] Padjasek M, Qasem B, Cislo-Pakuluk A, et al. Cyclosporine a delivery platform for veterinary ophthalmology—a new concept for advanced ophthalmology. Biomolecules. 2022; 12(10):1525.

[113] Zhao D, Zhao H, He Y, Zhang M. BMSC alleviates dry eye by inhibiting the ROS-NLRP3-IL-1β signaling axis by reducing inflammation levels. Curr Eye Res. 2024; 49(7): 698-707.

[114] Ding N, Wei Q, Xu Q, et al. Acupuncture alleviates corneal inflammation in New Zealand white rabbits with dry eye diseases by regulating α7nAChR and NF-κB signaling pathway. Evid Based Complement Alternat Med. 2022; 2022: 1-12.

[115] Wu X, Ding N, Liang S, et al. Electroacupuncture improves scopolamine hydrobromide induced dry eye in mice via inhibiting ocular surface inflammation and regulating the HMGB1-related signaling pathways. Front Med. 2025; 12:1664376.

[116] Ding N, Wei Q, Deng W, Sun X, Zhang J, Gao W. Electroacupuncture alleviates inflammation of dry eye diseases by regulating the α7nAChR/NF-κB signaling pathway. Oxidative Med Cell Longev. 2021; 2021(1):6673610.

[117] Ho T-C, Yeh S-I, Chen S-L, Tsao YP. Integrin αv and vitronectin prime macrophage-related inflammation and contribute the development of dry eye disease. Int J Mol Sci. 2021; 22(16):8410.

[118] Liu Z, Li Y, Bao J, et al. Astaxanthin ameliorates benzalkonium chloride–induced dry eye disease through suppressing inflammation and oxidative stress via Keap1-Nrf2/HO-1 signaling pathways. Animal Models Exp Med. 2025; 8(6): 1056-1079.

[119] Chu D, Zhao M, Rong S, et al. Dual-atom nanozyme eye drops attenuate inflammation and break the vicious cycle in dry eye disease. Nano Micro Lett. 2024; 16(1):120.

[120] Menon NG, Goyal R, Lema C, et al. Proteoglycan 4 (PRG4) expression and function in dry eye associated inflammation. Exp Eye Res. 2021; 208:108628.

[121] Kiliccioglu A, Oncel D, Celebi ARC. Autoimmune disease-related dry eye diseases and their placement under the revised classification systems: an update. Cureus. 2023; 15(12):e50276.

[122] Zha Z, Xiao D, Liu Z, et al. Endoplasmic reticulum stress induces ROS production and activates NLRP3 inflammasome via the PERK-CHOP signaling pathway in dry eye disease. Invest Ophthalmol Vis Sci. 2024; 65(14):34.

[123] Bereiter DA, Rahman M, Ahmed F, Thompson R, Luong N, Olson JK. P2x7 receptor activation and estrogen status drive neuroinflammatory mechanisms in a rat model for dry eye. Front Pharmacol. 2022; 13:827244.

[124] Fakih D, Guerrero-Moreno A, Baudouin C, Réaux-le Goazigo A, Parsadaniantz SM. Capsazepine decreases corneal pain syndrome in severe dry eye disease. J Neuroinflammation. 2021; 18(1):111.

[125] Jin T, Liu X, Li Y, et al. Electroacupuncture reduces ocular surface neuralgia in dry-eyed guinea pigs by inhibiting the trigeminal ganglion and spinal trigeminal nucleus caudalis P2X3R-PKC signaling pathway. Curr Eye Res. 2023; 48(6): 546-556.

[126] Wan M-M, Jin T, Fu Z-Y, Lai SH, Gao WP. Electroacupuncture alleviates dry eye ocular pain through TNF-ɑ mediated ERK1/2/P2X3R signaling pathway in SD rats. J Pain Res. 2023; 16: 4241-4252.

[127] Giannaccare G, Ghelardini C, Mancini A, Scorcia V, di Cesare Mannelli L. New perspectives in the pathophysiology and treatment of pain in patients with dry eye disease. J Clin Med. 2021; 11(1):108.

[128] Duan H, Zhou Y, Ma B, et al. Effect of acupuncture treatment on the ocular pain, mental state and ocular surface characteristics of patients with dry eye disease: a non-randomized pilot study. Clin Ophthalmol. 2024; 18: 2751-2764.

[129] Kastelan S, Kozina L, Tomic Z, et al. Dry eye disease and psychiatric disorders: neuroimmune mechanisms and therapeutic perspectives. Int J Mol Sci. 2025; 26(21):10699.

[130] Fang W, Lin ZX, Yang HQ, Zhao L, Liu DC, Pan ZQ. Changes in corneal nerve morphology and function in patients with dry eyes having type 2 diabetes. World J Clin Cases. 2022; 10(10): 3014-3026.

[131] Uchino Y, Uchino M, Mizuno M, Shigeno Y, Furihata K, Shimazaki J. Morphological alterations in corneal nerves of patients with dry eye and associated biomarkers. Exp Eye Res. 2023; 230:109438.

[132] Jing D, Liu Y, Chou Y, et al. Change patterns in the corneal sub-basal nerve and corneal aberrations in patients with dry eye disease: an artificial intelligence analysis. Exp Eye Res. 2022; 215:108851.

[133] Ma B, Li H, Wang Y, et al. Influence of immune cells on corneal nerve morphological analysis and clinical relevance in diabetes-related dry eye. Transl Vis Sci Technol. 2025; 14(7):16.

[134] Liu Y, Ma B, Zhao L, et al. Influence of dendritic cells on corneal nerve morphological analysis and clinical relevance in chronic dry eye disease after femtosecond laser-assisted laser in situ keratomileusis. Front Med. 2025; 12:1568787.

[135] Kaser E, Reymond E, Nosch DS. Corneal sensitivity in dry eye disease: a systematic review. Ocul Surf. 2025; 39: 1-16.

[136] Maity M, Allay MB, Ali MH, Deshmukh R, Basu S, Singh S. Association of tear osmolarity and corneal nerves structure in dry eye disease: an in vivo study. Graefes Arch Clin Exp Ophthalmol. 2024; 263(3): 753-760.

[137] Kiyoi T, Nakajima A, He Q, et al. Tear deficiency transforms spatial distribution of corneal calcitonin gene-related peptide-positive nerves in rats. Front Cell Neurosci. 2025; 19:1619310.

[138] Gong Q, Huang K, Li K, et al. Structural and functional changes of binocular corneal innervation and ocular surface function after unilateral SMILE and tPRK. Br J Ophthalmol. 2024; 108(11): 1492-1499.

[139] Sonkodi B, Marsovszky L, Csorba A, et al. Disrupted neural regeneration in dry eye secondary to ankylosing spondylitis-with a theoretical link between Piezo2 Channelopathy and gateway reflex, WDR neurons, and flare-ups. Int J Mol Sci. 2023; 24(20):15455.

[140] Pham TL, Bazan HEP. Docosanoid signaling modulates corneal nerve regeneration: effect on tear secretion, wound healing, and neuropathic pain. J Lipid Res. 2021; 62:100033.

[141] Li S, Xie J, Xiang J, et al. Corneal sensory nerve injury disrupts lacrimal gland function by altering circadian rhythms in mice. Invest Ophthalmol Vis Sci. 2025; 66(4): 40.

[142] Daryabari SH, Ghasemian M, Lotfi E, et al. Placental-derived products for corneal regeneration: applications of amniotic membrane, cord blood serum, and stem cells: a review. Transplant Cell Ther. 2025; 32: 13-45.

[143] Prasad D, Jakati S, Bokara KK, Basu S, Singh V, Donthineni PR. Comparative assessment of structural and tear film alterations in rabbit meibomian gland dysfunction models using chemical and electrocauterization techniques. Sci Rep. 2025; 15(1):23494.

[144] Wu Y, Ye H, Zhang H, et al. Characterizing inflammatory, nerve innervation, and immune alterations in three dry eye disease animal models. Exp Eye Res. 2025; 260:110580.

[145] Zhang R, Pandzic E, Park M, Wakefield D, di Girolamo N. Inducing dry eye disease using a custom engineered desiccation system: impact on the ocular surface including keratin-14-positive limbal epithelial stem cells. Ocul Surf. 2021; 21: 145-159.

[146] Steven P, Schwab S, Kiesewetter A, Saban DR, Stern ME, Gehlsen U. Disease-specific expression of conjunctiva associated lymphoid tissue (CALT) in mouse models of dry eye disease and ocular allergy. Int J Mol Sci. 2020; 21(20):7514.

[147] Naderi A, Taketani Y, Wang S, et al. Topical neurokinin-1 receptor antagonism ameliorates ocular pain and prevents corneal nerve degeneration in an animal model of dry eye disease. Pain Rep. 2025; 10(1):e1232.

[148] Honkanen R, Nemesure B, Huang L, Rigas B. Diagnosis of dry eye disease using principal component analysis: a study in animal models of the disease. Curr Eye Res. 2021; 46(5): 622-629.

[149] Yu K, Asbell PA, Shtein RM, Ying GS, for Dry Eye Assessment and Management Study Research Group. Dry eye subtypes in the dry eye assessment and management (DREAM) study: a latent profile analysis. Transl Vis Sci Technol. 2022; 11(11):13.

[150] Yu K, Bunya V, Maguire M, Asbell P, Ying GS, Dry Eye Assessment and Management Study Research Group. Systemic conditions associated with severity of dry eye signs and symptoms in the dry eye assessment and management study. Ophthalmology. 2021; 128(10): 1384-1392.

[151] Kitazawa K, Inomata T, Shih K, et al. Impact of aging on the pathophysiology of dry eye disease: a systematic review and meta-analysis. Ocul Surf. 2022; 25: 108-118.

[152] Wang Z, Song X, Wei Y, Wu X, Jie Y. Cytisine eye drops for benzalkonium chloride-induced dry eye: safety and efficacy evaluation. Pharm Dev Technol. 2024; 29(5): 457-467.

[153] Tong X, Chen L, He S-J, Zuo JP. Artemisinin derivative SM934 in the treatment of autoimmune and inflammatory diseases: therapeutic effects and molecular mechanisms. Acta Pharmacol Sin. 2022; 43(12): 3055-3061.

[154] Katsinas N, Gehlsen U, Garcia-Posadas L, et al. Olive pomace phenolic compounds: from an agro-industrial by-product to a promising ocular surface protection for dry eye disease. J Clin Med. 2022; 11(16):4703.

[155] Thacker M, Singh V, Basu S, Singh S. Biomaterials for dry eye disease treatment: current overview and future perspectives. Exp Eye Res. 2023; 226:109339.

[156] Rodella U, Bosio L, Giurgola L, et al. 18 A porcine cornea and lamellar tissue model to investigate effects of storage conditions on corneal preservation. BMJ Open Ophthalmol. 2022; 7(Suppl 2): A8.

[157] Son A, Park J, Kim W, et al. Recent advances in omics, computational models, and advanced screening methods for drug safety and efficacy. Toxics. 2024; 12(11):822.

[158] Bai C, Wu L, Li R, Cao Y, He S, Bo X. Machine learning-enabled drug-induced toxicity prediction. Adv Sci (Weinh). 2025; 12(16):e2413405.

[159] Azevedo C, Andersen JT, Traverso G, Sarmento B. The potential of porcine ex vivo platform for intestinal permeability screening of FcRn-targeted drugs. Eur J Pharm Biopharm. 2021; 162: 99-104.

[160] Kumari S, Dandamudi M, Rani S, et al. Dexamethasone-loaded nanostructured lipid carriers for the treatment of dry eye disease. Pharmaceutics. 2021; 13(6):905.

[161] Voss S, Behrmann T, Reichl S. Development of in vitro dry eye models to study proliferative and anti-inflammatory effects of allogeneic serum eye drops. Int J Mol Sci. 2023; 24(2):1567.

[162] Krstic L, Vallejo R, Rodriguez-Rojo S, et al. Effective ocular delivery of antioxidant polyphenols using elastin-like polymer nanosystems developed by sustainable process. Int J Pharm. 2025; 678:125691.

[163] Galindo S, de la Mata A, López-Paniagua M, et al. Subconjunctival injection of mesenchymal stem cells for corneal failure due to limbal stem cell deficiency: state of the art. Stem Cell Res Ther. 2021; 12(1): 60.

[164] Chaudhari P, Ghate VM, Nampoothiri M, Lewis SA. Cyclosporine a eluting nano drug reservoir film for the management of dry eye disease. AAPS PharmSciTech. 2025; 26(5):109.

[165] Sommi A, Li G, Hwang J, Klawe J, Johnson B, Ahmad S. Association of dry eye and corneal ulcers with collagen vascular diseases in a medicare population. Cornea. 2025. Epub ahead of print.

[166] Ruiz-Lozano RE, Prida-Espaillat LA, Moll-Auais RA, et al. Ocular inflammatory manifestations in patients with rheumatoid arthritis. Reumatol Clín. 2025; 21(5):501891.

[167] Jacobi C. What is important in diagnosing dry eye disease—recommendations according to current guidelines (DEWS II, DOG/BVA). Klin Monatsbl Augenheilkd. 2022; 239(10): 1273-1286.

[168] Stapleton F, Argüeso P, Asbell P, et al. TFOS DEWS III: Digest. Am J Ophthalmol. 2025; 279: 451-553.

[169] Gurnani B, Kaur K. Biosensor-embedded wearables for dry eye monitoring and management. Expert Rev Med Devices. 2025; 22(10): 1073-1079.

[170] Joshi VP, Singh S, Thacker M, et al. Newer approaches to dry eye therapy: nanotechnology, regenerative medicine, and tissue engineering. Indian J Ophthalmol. 2023; 71(4): 1292-1303.

[171] Almulhim A. Therapeutic targets in the management of dry eye disease associated with Sjogren's syndrome: an updated review of current insights and future perspectives. J Clin Med. 2024; 13(6):1777.

[172] Rák T, Csutak A. Exploring novel pharmacological trends: natural compounds in dry eye disease management. Acta Pharma. 2024; 74(3): 383-404.

[173] Bouazza M, Youssefi H, Bouanani N. Ocular Manifestations in Hematological Disorders. Cureus; 2022.

[174] Ng SL, Tey A, Sellappans R, et al. Challenges and opportunities in community pharmacists' identification and management of dry eye disease: a qualitative study. Int J Pharm Pract. 2025; 33(3): 292-299.

[175] Lipps AJ, Jang K. Social work research and evidence-based practice in experimental medicine exploring issues in the xenotransplantation context. J Evid Based Soc Work. 2020; 18: 1-17.

RIGHTS & PERMISSIONS

2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.